胰高血糖素样肽-1受体激动剂对改善2型糖尿病伴代谢相关脂肪性肝病的作用机制的研究进展

Research progress on the mechanism of glucagon-like peptide-1 receptor agonists in improving glycolipid levels and liver fat in patients with type 2 diabetes and metabolic-related fatty liver disease

随着社会经济发展以及饮食结构的变化,代谢相关脂肪肝病(MAFLD)现已发展为一类常见肝病,常见于2型糖尿病患者,但缺乏治疗该病的批准药物.研究表明,胰高血糖素样肽-1(GLP-1)受体激动剂通过促胰素直接影响肝细胞炎症反应、脂质代谢以及氧化应激,不仅可以有效治疗T2DM,还有利于逆转MAFLD的病情发展.本文主要探究GLP-1受体激动剂在2型糖尿病伴代谢相关脂肪性肝病患者中的作用原理.

Metabolism-associated fatty liver disease(MAFLD)has evolved into a common liver disease with socioeconomic development and changes in dietary structure,and is commonly seen in patients with type 2 diabetes mellitus,but there is a lack of approved medications to treat this disease.Studies have shown that glucagon-like peptide 1(GLP-1)receptor agonists can not only effectively treat T2DM,but also help to reverse the progression of MAFLD by directly affecting hepatocyte inflammation,lipid metabolism,and oxidative stress through glucagon.This article focuses on the principle of GLP-1 receptor agonists in patients with type 2 diabetes mellitus with metabolism-associated fatty liver disease.